Board of Directors
Tim McCarthy (Chairman)
21.08.56
Tim has 40 years’ international senior level business experience in the Healthcare, Biotech and Technology sectors.
He is also CEO of ImmuPharma plc an AIM quoted specialist drug discovery and development company and Chairman of 4basebio PLC, an AIM quoted company developing next generation gene therapy technologies and solutions.
Tim is a former CEO and Finance Director of a number of public and private companies, including Alizyme plc and Peptide Therapeutics Group plc. He has also co-founded a number of healthcare and biotechnology companies. A Fellow of the Association of Chartered Certified Accountants, he also has an MBA from Cranfield School of Management.
Dr Simon Ward (Chief Executive Officer)
7.10.68
Simon is a co-founder of Incanthera and has more than 30 years’ senior experience in academia and business.
He was a founder and CEO of Molecular SkinCare Limited, a pioneer and developer of novel dermatology products for the prevention and management of skin diseases. As CSO of York Pharma plc, he was responsible for bringing innovative dermatology product through to market. Simon also served as chairman of South Yorkshire Bioscience Enterprise Network (SYBEN) and deputy chairman of Medipex, a healthcare innovation hub for NHS organisations across industry and academia internationally.
Simon graduated from the University of London’s School of Pharmacy (UK) with a Joint Honours Degree in Pharmacology and Toxicology and was awarded a DPhil in the Department of Human Anatomy, Oxford University under a Glaxo Group Research Studentship.
John Howes (Senior Independent Director)
02.07.55
With more than 43 years’ experience in UK equity capital markets, John brings a wealth of knowledge and Institutional relationships to Stanford Capital Partners. John has extensive experience in the UK equity capital markets building an established reputation in the small and mid-cap sectors, holding previous positions as Partner with Matrix Corporate Capital and senior positions at Seymour Pierce, Panmure Gordon, Northland Capital and Stanford Capital.
Caroline Murray (Non-Executive Director)
26.02.70
Caroline’s expertise across healthcare, market positioning and strategic implementation brings extensive product management, and marketing and commercialisation experience to the Board. Senior positions held in the pharmaceutical industry, including both Novartis and Bristol Myers Squibb, over 30 years, combine dermatology, healthcare and commercial skills, perfectly suited to the company’s goals.
Key Senior Management
Laura Jane Brogden (Chief Financial Officer)
Laura Brogden has 20 years’ experience heading up the finance function for SMEs across a diverse range of industries
She is also a Partner in Fact3 LLP which provides accounting, HR and IT support for SMEs.
Laura is an Associate of the Chartered Institute of Management Accountants.
Suzanne Brocks (Head of Communications & Company Secretary)
Suzanne has over 30 years’ City experience.
She was a Senior Director in Financial and Corporate Communications with Buchanan Communications, advising on IPOs and mergers and acquisitions, in addition to general financial public relations consultancy and strategic direction for a wide range of public companies. Previously Suzanne was a Relationship Manager in private banking with Hill Samuel advising clients in London and the Far East.